It could potentially. The point I would make is that it could also elevate the standards for demonstrating improvement over existing therapies. What we see right now, unfortunately, is that a lot of new medications aren't terribly important for advancing care and health care outcomes. They are me-too drugs, and so on. I think this kind of body could encourage greater innovation that is in line with improved health care outcomes.
On May 30th, 2016. See this statement in context.